389 related articles for article (PubMed ID: 9862789)
1. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
2. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
3. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
Pharm Res; 1998 Jul; 15(7):1001-6. PubMed ID: 9688051
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
5. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
Martin C; Berridge G; Higgins CF; Callaghan R
Br J Pharmacol; 1997 Oct; 122(4):765-71. PubMed ID: 9375975
[TBL] [Abstract][Full Text] [Related]
6. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?
Ofer M; Wolffram S; Koggel A; Spahn-Langguth H; Langguth P
Eur J Pharm Sci; 2005 Jun; 25(2-3):263-71. PubMed ID: 15911222
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
8. Pumping of drugs by P-glycoprotein: a two-step process?
Litman T; Skovsgaard T; Stein WD
J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells.
Brouillard F; Tondelier D; Edelman A; Baudouin-Legros M
Cancer Res; 2001 Feb; 61(4):1693-8. PubMed ID: 11245485
[TBL] [Abstract][Full Text] [Related]
10. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
Garrigues A; Nugier J; Orlowski S; Ezan E
Anal Biochem; 2002 Jun; 305(1):106-14. PubMed ID: 12018951
[TBL] [Abstract][Full Text] [Related]
11. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery.
Balimane PV; Patel K; Marino A; Chong S
Eur J Pharm Biopharm; 2004 Jul; 58(1):99-105. PubMed ID: 15207543
[TBL] [Abstract][Full Text] [Related]
12. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
13. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
15. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
16. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
18. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.
Romsicki Y; Sharom FJ
Biochemistry; 1999 May; 38(21):6887-96. PubMed ID: 10346910
[TBL] [Abstract][Full Text] [Related]
19. Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo.
Shirasaka Y; Masaoka Y; Kataoka M; Sakuma S; Yamashita S
Drug Metab Dispos; 2008 May; 36(5):916-22. PubMed ID: 18276834
[TBL] [Abstract][Full Text] [Related]
20. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
Yusa K; Tsuruo T
Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
